AGO Research GmbH
- Country
- 🇩🇪Germany
- Ownership
- Private
- Established
- 1993-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.ago-ovar.de
Pembrolizumab in Combination With Lenvatinib in Pts With Recurrent, Persistent, Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy
- Conditions
- Interventions
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- AGO Research GmbH
- Target Recruit Count
- 42
- Registration Number
- NCT05903833
Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi
- Conditions
- Interventions
- First Posted Date
- 2021-11-19
- Last Posted Date
- 2022-07-27
- Lead Sponsor
- AGO Research GmbH
- Target Recruit Count
- 100
- Registration Number
- NCT05126342
WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- AGO Research GmbH
- Target Recruit Count
- 60
- Registration Number
- NCT04644289
- Locations
- 🇩🇪
Universitätsklinikum Mannheim GmbH, Frauenklinik, Mannheim, Baden-Württemberg, Germany
🇩🇪Mammazentrum HH am Krankenhaus Jerusalem, Gynäkologisches Operationszentrum Hamburg, Hamburg, Germany
🇩🇪Charité Berlin, Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie, Berlin, Germany
Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-02-18
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- AGO Research GmbH
- Target Recruit Count
- 136
- Registration Number
- NCT04274426
- Locations
- 🇩🇪
Charite Campus Virchow Klinikum, Berlin, Germany
🇩🇪Städtische Klinikum Dessau, Dessau, Germany
🇩🇪Universitätsklinikum Carl-Gustav-Carus an der Technischen Universität Dresden, Dresden, Germany
Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-10-01
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- AGO Research GmbH
- Target Recruit Count
- 9
- Registration Number
- NCT03690739
- Locations
- 🇩🇪
Sozialstiftung Bamberg, Bamberg, Germany
🇩🇪Kreiskrankenhaus "Johann Kentmann", Torgau, Germany
🇩🇪Hochtaunus-Kliniken, Bad Homburg, Germany
Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-11-27
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- AGO Research GmbH
- Target Recruit Count
- 550
- Registration Number
- NCT03353831
- Locations
- 🇩🇰
Herlev University Hospital, Herlev, Denmark
🇩🇰Odense University Hospital, Odense, Denmark
🇫🇷Institut Bergonié, Bordeaux, France
Prevalence of BRCA in Patients With Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-08-21
- Last Posted Date
- 2021-06-16
- Lead Sponsor
- AGO Research GmbH
- Target Recruit Count
- 530
- Registration Number
- NCT02222883
- Locations
- 🇩🇪
Universitätsklinik Carl Gustav Carus, Dresden, Germany
🇩🇪Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
🇩🇪Evangelisches Krankenhaus, Düsseldorf, Germany
Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-04-23
- Last Posted Date
- 2021-07-13
- Lead Sponsor
- AGO Research GmbH
- Target Recruit Count
- 682
- Registration Number
- NCT01837251
- Locations
- 🇦🇺
ICON Cancer Care Centre, Milton, Australia
🇦🇺St. George Hospital, Kogarah, Australia
🇦🇺Mater Adult Hospital, South Brisbane, Australia